Final Analysis of Potential Drug-Drug Interactions between Highly Purified Cannabidiol (CBD) and Anti-Seizure Medications (ASMs) in an Open-Label Expanded Access Program.

This study confirms some previously identified interactions with CBD and identifies other potential pharmacokinetic interactions; however, the clinical significance of these observations is likely minor and there is no effect of time on these findings.